Hui Jun Lim1, Jia-Lin Yang2. 1. Sarcoma and Nano-oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, Faculty of Medicine, University of New South Wales, Randwick, NSW, Australia. 2. Sarcoma and Nano-oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, Faculty of Medicine, University of New South Wales, Randwick, NSW, Australia. Electronic address: j.yang@unsw.edu.au.
Abstract
PURPOSE: MicroRNAs (miRNAs) are single-stranded noncoding RNAs involved in various biological processes, including cell differentiation and development. They play multiple key roles as tumour suppressors, oncogenes or both in particular cases. This review aims to summarise current findings of the expression of miRNAs and their role in clinical oncology. Current knowledge regarding the involvement of miRNAs in different sarcoma subtypes will be assessed, in conjunction with their potential application as therapeutic targets. METHODS: Relevant articles in scientific databases were identified using a combination of search terms, including "microRNA," "deregulation," "sarcoma," and "targeted therapy". These databases included Medline, Embase, Cochrane Review, Pubmed and Scopus. RESULTS: Aberrant miRNA expression patterns have been identified in a range of sarcoma subtypes, and differences in miRNA expression profiles between malignant cells and their normal counterparts suggests that miRNAs play key roles in sarcoma development. The identification of unique miRNA patterns in individual tumour types could possibly be used as a diagnostic tool in sarcoma. Moreover, identification of these miRNAs provides novel targets for the development of therapeutic strategies in distinct sarcoma subtypes. CONCLUSION: miRNAs hold significant potential as diagnostic biomarkers, as well as therapeutic targets in sarcoma. Possible future clinical applications include the use of miRNA pathways as therapeutic targets or miRNA expression profiling as a means of patient selection. The involvement miRNAs will undoubtedly contribute to the advancement of future targeted therapeutic interventions in sarcoma, and further establishment of appropriate delivery systems is vital for their use in clinical settings.
PURPOSE: MicroRNAs (miRNAs) are single-stranded noncoding RNAs involved in various biological processes, including cell differentiation and development. They play multiple key roles as tumour suppressors, oncogenes or both in particular cases. This review aims to summarise current findings of the expression of miRNAs and their role in clinical oncology. Current knowledge regarding the involvement of miRNAs in different sarcoma subtypes will be assessed, in conjunction with their potential application as therapeutic targets. METHODS: Relevant articles in scientific databases were identified using a combination of search terms, including "microRNA," "deregulation," "sarcoma," and "targeted therapy". These databases included Medline, Embase, Cochrane Review, Pubmed and Scopus. RESULTS: Aberrant miRNA expression patterns have been identified in a range of sarcoma subtypes, and differences in miRNA expression profiles between malignant cells and their normal counterparts suggests that miRNAs play key roles in sarcoma development. The identification of unique miRNA patterns in individual tumour types could possibly be used as a diagnostic tool in sarcoma. Moreover, identification of these miRNAs provides novel targets for the development of therapeutic strategies in distinct sarcoma subtypes. CONCLUSION: miRNAs hold significant potential as diagnostic biomarkers, as well as therapeutic targets in sarcoma. Possible future clinical applications include the use of miRNA pathways as therapeutic targets or miRNA expression profiling as a means of patient selection. The involvement miRNAs will undoubtedly contribute to the advancement of future targeted therapeutic interventions in sarcoma, and further establishment of appropriate delivery systems is vital for their use in clinical settings.
Authors: Radhakrishnan Vishnubalaji; Ramesh Elango; Muthurangan Manikandan; Abdul-Aziz Siyal; Dalia Ali; Ammar Al-Rikabi; Dana Hamam; Rimi Hamam; Hicham Benabdelkamel; Afshan Masood; Ibrahim O Alanazi; Assim A Alfadda; Musaad Alfayez; Abdullah Aldahmash; Moustapha Kassem; Nehad M Alajez Journal: Cell Death Discov Date: 2020-09-01
Authors: Shafaque Rahman; Jolien Vandewalle; Patricia H P van Hamersveld; Caroline Verseijden; Olaf Welting; Aldo Jongejan; Pierina Casanova; Sybren L Meijer; Claude Libert; Theodorus B M Hakvoort; Wouter J de Jonge; Sigrid E M Heinsbroek Journal: Cells Date: 2021-12-25 Impact factor: 6.600
Authors: Laura Gonzalez Dos Anjos; Bruna Cristine de Almeida; Thais Gomes de Almeida; André Mourão Lavorato Rocha; Giovana De Nardo Maffazioli; Fernando Augusto Soares; Isabela Werneck da Cunha; Edmund Chada Baracat; Katia Candido Carvalho Journal: Cancers (Basel) Date: 2018-09-06 Impact factor: 6.639